ABSTRACT

With an escalating side effect of chemotherapy and in depth knowledge of oncogenic signal transduction pathways, targeted therapies have emerged as an exciting advancement in the treatment of sepsis, and inflammatory and autoimmune diseases. Jab1-directed therapies might offer new treatment opportunities for cancer disease in the future with minimal side effects. Still, there are various hidden pockets resides in the cancer progression still which needs to be uncovered. Hence there is a strong need to reevaluate these mechanisms to elucidate new targets which could further aid in the development of targeted therapeutic approach. The present article concentrates on an upcoming therapeutic target, c-Jun activation domain-binding protein-1 (Jab1), a regulator of multiple protein interactions, integrin signaling, cell proliferation, apoptosis, genomic instability and DNA repair. Jab1 interacts with various nuclear receptors and activates transcription at the corresponding target genes which provide a firm basis for the link between the massive regulatory complexes containing nuclear receptor coactivators and the Jab1 containing signalosome. Our review may pave the way for targeting Jab1 for anti-cancer drug development and also provide an insight into the mechanisms for the development of inhibitory compounds against Jab1 which could be useful in the prevention of carcinogenesis with minimal side effects. Keywords: Carcinogenesis, Chemotherapy, CSN complex, Jab1, Natural compounds, In-silico

https://ijbpas.com/pdf/2018/January/1514650529MS IJBPAS 2017 4352.pdf

Download PDF